Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
June 23, 2022 07:24 AM EDT
R&D

No­var­tis pledges $250M in R&D fund­ing for ne­glect­ed trop­i­cal dis­eases, malar­ia

Amber Tong

Over the next five years, No­var­tis is pledg­ing to pour $250 mil­lion in­to R&D for new treat­ments of ne­glect­ed trop­i­cal dis­eases and malar­ia — with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times